Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:ERAS NASDAQ:HURA NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$8.33$8.07$6.85▼$20.96$491.59M-0.08319,693 shs306,595 shsERASErasca$1.71$1.42$1.01▼$3.45$484.42M1.05972,818 shs677,424 shsHURATuHURA Biosciences$2.84-3.7%$2.74$1.80▼$9.01$128.86M0.17419,804 shs248,886 shsKMDAKamada$7.78-1.6%$7.28$5.08▼$9.15$454.86M0.9655,323 shs19,082 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+2.71%+8.60%+9.89%+2.33%-60.07%ERASErasca+1.79%+18.75%+23.02%+22.14%-45.37%HURATuHURA Biosciences+7.66%+25.00%+16.60%-30.26%+294,999,900.00%KMDAKamada+3.53%+4.63%+8.95%+19.49%+34.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGEMCullinan Therapeutics1.4113 of 5 stars3.50.00.00.00.61.70.6ERASErasca2.1844 of 5 stars3.52.00.00.00.62.50.6HURATuHURA Biosciences1.8372 of 5 stars3.70.00.00.03.00.00.0KMDAKamada3.6005 of 5 stars3.33.00.00.00.01.73.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 3.00Buy$30.00260.14% UpsideERASErasca 3.00Buy$4.57167.34% UpsideHURATuHURA Biosciences 3.40Buy$12.67346.01% UpsideKMDAKamada 2.67Moderate Buy$13.0067.10% UpsideCurrent Analyst Ratings BreakdownLatest HURA, CGEM, KMDA, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AERASErascaN/AN/AN/AN/A$1.50 per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AKMDAKamada$160.95M2.78$0.48 per share16.09$4.51 per share1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)ERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%10/6/2025 (Estimated)KMDAKamada$14.46M$0.2926.8324.310.969.60%6.31%4.43%8/13/2025 (Estimated)Latest HURA, CGEM, KMDA, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CGEMCullinan Therapeutics-$0.7951N/AN/AN/AN/AN/A8/13/2025Q2 2025KMDAKamada$0.09N/AN/AN/A$158.59 millionN/A8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A11.6211.62ERASErascaN/A12.3512.35HURATuHURA BiosciencesN/A3.003.00KMDAKamadaN/A3.301.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%ERASErasca67.78%HURATuHURA Biosciences0.62%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics7.16%ERASErasca14.40%HURATuHURA Biosciences0.20%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3059.01 million54.79 millionOptionableERASErasca120283.29 million242.49 millionOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/AKMDAKamada36057.51 million36.75 millionOptionableHURA, CGEM, KMDA, and ERAS HeadlinesRecent News About These CompaniesKMDA or ACAD: Which Is the Better Value Stock Right Now?July 4, 2025 | zacks.comHuntleigh Advisors Inc. Buys New Stake in Kamada Ltd. (NASDAQ:KMDA)July 4, 2025 | marketbeat.comOn this day: Daichi Kamada signs for Palace!July 1, 2025 | cpfc.co.ukCStrength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength? - NasdaqJune 27, 2025 | nasdaq.comStrength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength?June 25, 2025 | msn.comKamada Stock Price HistoryJune 19, 2025 | investing.comKMDA vs. ACAD: Which Stock Is the Better Value Option?June 18, 2025 | zacks.comShould Value Investors Buy Kamada (KMDA) Stock?June 18, 2025 | msn.comKamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle EastJune 17, 2025 | globenewswire.comDaichi Kamada Highlights Quality Gap Between Indonesian and Australian National TeamsJune 12, 2025 | en.tempo.coEKamada nets brace in Japan rout as South Korea put four past KuwaitJune 10, 2025 | beinsports.comBKamada hits double as Japan thrash Indonesia 6-0June 10, 2025 | msn.comImplied Volatility Surging for Kamada Stock OptionsJune 10, 2025 | msn.comFootball: Daichi Kamada, Takefusa Kubo spur Japan to big win over IndonesiaJune 10, 2025 | mainichi.jpMWall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a BetJune 2, 2025 | zacks.comAre Investors Undervaluing Kamada (KMDA) Right Now?June 2, 2025 | zacks.comKMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?May 28, 2025 | zacks.comIs Kamada (KMDA) Stock Undervalued Right Now?May 16, 2025 | msn.comWall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to TradeMay 16, 2025 | msn.comCompared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key MetricsMay 15, 2025 | msn.comKamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ExpansionMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHURA, CGEM, KMDA, and ERAS Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$8.33 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.33 0.00 (0.00%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Erasca NASDAQ:ERAS$1.71 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.71 0.00 (0.00%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.TuHURA Biosciences NASDAQ:HURA$2.84 -0.11 (-3.73%) Closing price 04:00 PM EasternExtended Trading$2.80 -0.03 (-1.23%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Kamada NASDAQ:KMDA$7.78 -0.13 (-1.64%) Closing price 04:00 PM EasternExtended Trading$7.79 +0.01 (+0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
